Phosphorylation and activation of PFK-2 stimulate glycolysis and improves cardiac energetics [19,21,22] and, therefore, may serve as a novel therapeutic approach for the metabolic dysfunction in HF resulting from VO. The gene discussed is PFKFB3; the disease is hydrops fetalis.